LENZ Therapeutics sells VIZZ, a daily eye drop that improves near vision for adults with presbyopia. LENZ last reported earnings on Tue, Aug 11, 2026. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 30 | HC Wainwright & Co. | Target lowered | Buy | |
| Oct 29 | TD Cowen | Target lowered | Buy | |
| Oct 21 | TD Cowen | Maintained | Buy | |
| Oct 19 | Piper Sandler | Target lowered | Hold | |
| Aug 12 | Piper Sandler | Target lowered | Hold |
Whale Options Flow
90DNo whale options trades in LENZ in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LENZ is in one of them and how their past LENZ trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LENZ in an article yet. Here's the latest on the wider market.
About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company based in Solana Beach, California, that develops and sells treatments for eye conditions. Its main product is VIZZ, a daily eye drop that improves near vision for adults with presbyopia, the loss of close-up focus that comes with aging. The company sells VIZZ in the United States to eye care professionals such as optometrists and ophthalmologists, and to patients who buy it at retail pharmacies.
- Headquarters
- Solana Beach, CA